C19orf53

Across TCGA pan-cancer cohorts, C19orf53 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated C19orf53 data layer compared with 24 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher C19orf53 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated C19orf53 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

CCRCC, HNSC, and PDAC are the cancer types where C19orf53 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.868	1.000	.003	11	view →
HNSC	OS	Quartile	III,IV	0.480	0.778	.015	9	view →
PDAC	DFS	Median	III,IV	0.811	0.387	.020	8	view →
GBM	DFS	Quartile	All	0.308	0.493	.047	2	view →
LSCC	OS	Quartile	All	0.903	0.752	.036	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

C19orf53–CCRCC (DFS)

Open the CCRCC breakdown →